百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉称百济神州剽窃其BTK降解剂

金吾财讯09-12

金吾财讯 | 百济神州(BGNE)盘前跌超6%，截至发稿，报197.49美元。消息面上，据媒体，跨国药企艾伯维(ABBV)近期再次起诉了百济神州。理由是百济神州剽窃了其BTK降解剂（BTK degrader）的商业秘密。百济神州方面则表示，已获悉艾伯维近期向本公司提起一项诉讼，诉讼包含百济神州自主发现的化合物BGB-16673。百济神州将对艾伯维发起的指控开展坚决辩护，公司目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2466226357?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20210810/MTI5MjQwNzE0NzY0NzE5Ng==.jpg","is_english":false,"pubTime":"2024-09-12 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466226357","market":"nz","top_or_hot":-1,"title":"百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉 称百济神州剽窃其BTK降解剂","media":"金吾财讯","content":"<html><body><p>金吾财讯 | <a href=\"https://laohu8.com/S/688235\">百济神州</a>(BGNE)盘前跌超6%，截至发稿，报197.49美元。消息面上，据媒体，跨国药企艾伯维(ABBV)近期再次起诉了<a href=\"https://laohu8.com/S/06160\">百济神州</a>。理由是百济神州剽窃了其BTK降解剂（BTK degrader）的商业秘密。百济神州方面则表示，已获悉艾伯维近期向本公司提起一项诉讼，诉讼包含百济神州自主发现的化合物BGB-16673。百济神州将对艾伯维发起的指控开展坚决辩护，公司目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉 称百济神州剽窃其BTK降解剂</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉 称百济神州剽窃其BTK降解剂\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 17:12 北京时间&nbsp;&nbsp;&nbsp;<a href=279833><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 百济神州(BGNE)盘前跌超6%，截至发稿，报197.49美元。消息面上，据媒体，跨国药企艾伯维(ABBV)近期再次起诉了百济神州。理由是百济神州剽窃了其BTK降解剂（BTK degrader）的商业秘密。百济神州方面则表示，已获悉艾伯维近期向本公司提起一项诉讼，诉讼包含百济神州自主发现的化合物BGB-16673。百济神州将对艾伯维发起的指控开展坚决辩护，公司目前在仔细核阅艾伯维的...</p>\n\n<a href=\"279833\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1244550221.USD","symbol_name":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","start_time":0,"source_url":"279833","article_id":"2466226357","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/MTI5MjQwNzE0NzY0NzE5Ng==.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466226357","pubTimestamp":1726132337,"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 百济神州(BGNE)盘前跌超6%，截至发稿，报197.49美元。消息面上，据媒体，跨国药企艾伯维(ABBV)近期再次起诉了百济神州。理由是百济神州剽窃了其BTK降解剂（BTK degrader）的商业秘密。百济神州方面则表示，已获悉艾伯维近期向本公司提起一项诉讼，诉讼包含百济神州自主发现的化合物BGB-16673。百济神州将对艾伯维发起的指控开展坚决辩护，公司目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4535":"淡马锡持仓","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4559":"巴菲特持仓","BGNE":"百济神州","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","ABBV":"艾伯维公司","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK0239":"医药制造","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK1161":"生物科技","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0122379950.USD":"贝莱德世界健康科学A2","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","06160":"百济神州","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","BK1588":"回港中概股","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4585":"ETF&股票定投概念","BK1500":"做空集合股","BK4139":"生物科技","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4566":"资本集团","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC"},"translate_title":"BeiGene (BGNE) fell more than 6% before the market and was sued again by AbbVie (ABBV), claiming that BeiGene plagiarized its BTK degrader","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"ABBV":1,"BGNE":1,"06160":1},"content_text":"金吾财讯 | 百济神州(BGNE)盘前跌超6%，截至发稿，报197.49美元。消息面上，据媒体，跨国药企艾伯维(ABBV)近期再次起诉了百济神州。理由是百济神州剽窃了其BTK降解剂（BTK degrader）的商业秘密。百济神州方面则表示，已获悉艾伯维近期向本公司提起一项诉讼，诉讼包含百济神州自主发现的化合物BGB-16673。百济神州将对艾伯维发起的指控开展坚决辩护，公司目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466226357"}

百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉 称百济神州剽窃其BTK降解剂

精彩评论

百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉称百济神州剽窃其BTK降解剂